ALIOF (OTCMKTS:ALIOF – Get Free Report) and Lifecore Biomedical (NASDAQ:LFCR – Get Free Report) are both healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, dividends, profitability, risk, valuation, earnings and analyst recommendations.
Insider and Institutional Ownership
83.4% of Lifecore Biomedical shares are owned by institutional investors. 32.7% of Lifecore Biomedical shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
Valuation & Earnings
This table compares ALIOF and Lifecore Biomedical”s revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| ALIOF | N/A | N/A | N/A | N/A | N/A |
| Lifecore Biomedical | $128.87 million | 1.37 | -$40.50 million | ($1.07) | -4.35 |
ALIOF has higher earnings, but lower revenue than Lifecore Biomedical.
Analyst Recommendations
This is a summary of recent ratings for ALIOF and Lifecore Biomedical, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| ALIOF | 0 | 0 | 0 | 0 | 0.00 |
| Lifecore Biomedical | 1 | 2 | 1 | 0 | 2.00 |
Lifecore Biomedical has a consensus price target of $6.50, indicating a potential upside of 39.78%. Given Lifecore Biomedical’s stronger consensus rating and higher possible upside, analysts clearly believe Lifecore Biomedical is more favorable than ALIOF.
Profitability
This table compares ALIOF and Lifecore Biomedical’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| ALIOF | N/A | N/A | N/A |
| Lifecore Biomedical | -29.93% | N/A | -16.16% |
Summary
Lifecore Biomedical beats ALIOF on 6 of the 8 factors compared between the two stocks.
About ALIOF
Actelion Ltd. develops, produces and markets pharmaceutical drugs. The firm engages in research, development, manufacturing, and distribution of pharmaceutical, biological, and diagnostic products. The company was founded by Jean-Paul Clozel, Martine Clozel, Walter Fischli, André J. Müller and Thomas Widmann on December 30, 1999 and is headquartered in Allschwil, Switzerland.
About Lifecore Biomedical
Lifecore Biomedical, Inc., together with its subsidiaries, operates as an integrated contract development and manufacturing organization in the United States and internationally. The company engages in the manufacturing of pharmaceutical-grade sodium hyaluronate (HA) in bulk form, as well as formulated and filled syringes and vials for injectable products used in treating a range of medical conditions and procedures. It also provides services, such as technology development, material component changes, analytical method development, formulation development, pilot studies, stability studies, process validation, and production of materials for clinical studies to its partners for HA-based and non-HA based aseptically formulated and filled products. The company was formerly known as Landec Corporation and changed its name to Lifecore Biomedical, Inc. in November 2022. Lifecore Biomedical, Inc. was founded in 1965 and is headquartered in Chaska, Minnesota.
Receive News & Ratings for ALIOF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ALIOF and related companies with MarketBeat.com's FREE daily email newsletter.
